Cellenion

Executive Summary

Cellenion is a French biotechnology company that develops precision microdispensing instruments and consumables for single-cell and 3D cellular model workflows. Founded in 2014 and headquartered in Lyon, the company's flagship cellenONE® platform combines advanced imaging with picolitre dispensing, enabling high-precision single-cell isolation, dispensing, and recovery for applications in single-cell omics, cell line engineering, and microbiology. As a subsidiary of SCIENION, Cellenion leverages over two decades of expertise in microarray and nanoliter dispensing to serve academic and industrial research labs globally. The company operates at the pre-clinical stage, focusing on providing tools that address the growing demand for reproducible and scalable single-cell workflows in drug discovery and cell therapy development. Cellenion occupies a niche but strategic position in the life sciences tools market, with its technology gaining traction among researchers requiring high viability and accuracy in single-cell handling. While the company has not publicly disclosed funding details or commercial traction, its products are already used by leading research institutions. The main risk is the competitive landscape, with established players like 10x Genomics and emerging microfluidics alternatives. However, Cellenion's unique combination of imaging and picolitre dispensing offers differentiation. The company's success hinges on expanding its customer base, securing partnerships with biopharma, and scaling production. With a focused product portfolio and a strong parent company, Cellenion is well-positioned to capture a share of the growing single-cell analysis market, estimated to reach $3.2 billion by 2026.

Upcoming Catalysts (preview)

• Q3 2026Launch of cellenONE® next-generation platform60% success
• Q4 2026Strategic partnership with a top-10 pharma company for cell line development40% success
• Q1 2027Series A funding round to scale manufacturing and commercial expansion50% success